Aligos Stock Soars on China Hepatitis B Drug Deal

Key Deal Sparks Stock Surge

Aligos Therapeutics Inc. (NASDAQ:ALGS) shares climbed 20% following the announcement of an exclusive licensing agreement with Xiamen Amoytop Biotech Co., Ltd. The deal concerns the development and commercialization of pevifoscorvir sodium, a treatment for chronic hepatitis B virus, in Greater China.

Agreement Financials

Under the terms, Aligos will receive a $25 million upfront payment. The company is also eligible for up to $420 million in future clinical, regulatory, and sales milestones. This is supplemented by tiered, high single-digit royalties on net sales within the licensed territories, which include Mainland China, Taiwan, Hong Kong, and Macau. Aligos stated the deal extends its cash runway into the fourth quarter of 2026.

Strategic Market Impact

The partnership targets over 90 million individuals living with HBV in Greater China. Amoytop will fund the drug's development program in the region. Aligos retains full development and commercialization rights for pevifoscorvir sodium in other major markets, including the United States, Europe, and Japan. The transaction is pending Amoytop shareholder approval.

Summary and Outlook

The market's positive reaction underscores investor confidence in the potential of pevifoscorvir sodium. The successful closure of this deal will provide significant non-dilutive funding for Aligos while expanding its drug's reach into a critical market.

FAQ

Q: Why did Aligos (ALGS) stock increase?
A: The stock rose 20% due to an exclusive licensing deal with a Chinese firm for its hepatitis B drug, potentially worth up to $445 million plus royalties.

Q: What is pevifoscorvir sodium?
A: It is an investigational capsid assembly modulator under development for chronic HBV infection, designed to block virus replication.

Source: Investing.com